We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 29.50 | 1.94% | 1,553.00 | 5,189,535 | 16:35:08 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,555.00 | 1,555.50 | 1,557.50 | 1,521.50 | 1,525.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 12.99 | 62.72B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 18:55:55 | O | 100,321 | 1,669.26 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/7/2024 | 12:07 | ALNC |  GSK announces promising trial data for ViiV Healthcare HIV drugs |
| 19/7/2024 | 10:36 | UK RNS | GSK PLC Blenrep EMA Filing Acceptance |
| 19/7/2024 | 08:12 | ALNC | GSK drug for multiple myeloma accepted for European regulatory review |
| 18/7/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 16/7/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 15/7/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 14/7/2024 | 11:18 | ALNC | GSK moves to new global headquarters in return to central London |
| 12/7/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 08/7/2024 | 13:32 | ALNC | IN THE KNOW: UBS downgrades GSK and hacks share price target |
| 03/7/2024 | 09:22 | ALNC | TOP NEWS: GSK inks licensing deal with CureVac for flu and Covid drugs |
Gsk (GSK) Share Charts1 Year Gsk Chart |
|
1 Month Gsk Chart |
Intraday Gsk Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/7/2024 | 16:51 | Glaxosmithkline - The recovery | 33,171 |
| 03/6/2024 | 08:21 | GlazoSmithKline - News & Information | 145 |
| 24/9/2023 | 21:42 | GLAXOSMITHKLINE WITH CHARTS & NEWS | 188 |
| 17/4/2023 | 19:25 | Gsk zantac | 1 |
| 28/2/2023 | 16:35 | GSK launched Shingrix, which has a far superior shingles prevention effect | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 17:55:57 | 1,669.26 | 100,321 | 1,674,618.32 | O |
| 2024-07-26 15:49:12 | 1,553.00 | 8 | 124.24 | O |
| 2024-07-26 15:39:54 | 1,553.00 | 2,580 | 40,067.40 | AT |
| 2024-07-26 15:39:13 | 1,553.00 | 5,160 | 80,134.80 | AT |
| 2024-07-26 15:39:12 | 1,553.00 | 7,740 | 120,202.20 | AT |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Gsk Daily Update Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,523.50p.Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £64,019,869,961. Gsk has a price to earnings ratio (PE ratio) of 12.99. This morning GSK shares opened at 1,525p |
Posted at 23/7/2024 15:33 by tradermichael GSK PLC on Tuesday reported "positive" data for testing on three different treatments by ViiV Healthcare, its majority-owned specialist HIV company.The London-based pharmaceutical company firstly said ViiV Healthcare has shared 48-week findings from the phase 4 Paso Doble clinical trial investigating the two-drug regimen Dovato compared with the three-drug regimen Biktarvy for HIV. Dovato comprises dolutegravir and lamivudine, while the Biktarvy regimen consists of bictegravir, emtricitabine and tenofovir alafenamide fumarate. The trial, GSK said, focused on patients "who are virologically suppressed and who could benefit from treatment optimisation". The 48-week results showed that virologically suppressed adults with HIV, if they switched to the Dovato regimen, demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to Biktarvy. Secondly GSK said ViiV, in which Pfizer Inc and Shionogi & Co Ltd also hold minority interests, announced positive data for HIV drug Apretude, or cabotegravir LA for PrEP, in pregnant people. The new maternal safety and pregnancy outcomes and pharmacokinetic findings came from the HIV Prevention Trials Network's 084 open label extension, which evaluated cisgender women in sub-Saharan Africa who became pregnant while using Apretude for HIV pre-exposure prophylaxis, or PrEP. "The findings showed that [Apretude] was generally well tolerated among pregnant women, and PK findings demonstrated that cabotegravir levels were maintained above those associated with HIV protection throughout the overall pregnancy period," GSK said. Finally, GSK and ViiV announced phase 1 study results and in vitro data for VH4524184 or VH184, an investigational integrase strand transfer inhibitor or INSTI. ViiV, GSK said, shared positive in vitro findings showing that VH184 retained its antiviral activity and could be effective in countering second-generation INSTI resistance. Analysis of the phase 1 study, meanwhile, showed that PK and safety data supported the further development of VH184. "The study showed VH184 achieved drug levels in the blood that could potentially exhibit sufficient antiviral activity against the clinically derived INSTI mutations seen in vitro," GSK explained. |
Posted at 16/7/2024 09:51 by tradermichael Drugs giant GSK is set to move its global headquarters back to central London, ending more than two decades at its Brentford base.Around 3,000 employees will work from The Earnshaw building on the corner of New Oxford Street from Tuesday. It marks the end of its time at the Brentford site in west London after the £315 million building was officially opened in 2002 by then prime minister Tony Blair. GSK’s new HQ will house the firm’s leadership team – headed by chief executive Dame Emma Walmsley – as well as units supporting research and development, supply chain, commercial operations, corporate functions and its ViiV Healthcare specialist HIV joint venture. It sees GSK return to central London, where the company traces its roots back to the Plough Court Pharmacy, founded in the City in 1715. GSK said on announcing the new global HQ in December 2022 that the six-floor building would be designed with hybrid working in mind, including technology to support remote working, while also aiming to be energy efficient to help meet the firm’s 2030 net zero goals. Dame Emma said at the time: “We are proud to call London our home and look forward to the opportunities for even closer collaboration with the city’s world-class science, academic and healthcare institutions.” |
Posted at 05/7/2024 20:08 by xtrmntr It has been a turbulent few months for GSK (GSK) and its investors. The group hiked earnings guidance in May after a strong first quarter, only to see its shares tumble a few weeks later following an inauspicious ruling in the litigation cases relating to heartburn drug Zantac. Now it appears a revised recommendation from US health regulators will hurt sales of one of the company's key vaccines, Arexvy.The jab is designed to protect adults against RSV, a common respiratory virus that can cause serious illness in vulnerable individuals. Both Pfizer (US:PFE) and Moderna (US:MRNA) have produced competitor vaccines, although Arexvy was the first on the market. Last year, the Centers for Disease Control and Prevention (CDC) advised everyone over 60 to get immunised against RSV which was seemingly good news for market leader GSK.However, after reviewing the data, a CDC committee said vaccines should be restricted to the 75-plus cohort, with exceptions for 60-74 years olds with pre-existing conditions. "This move was characterised by one speaker as protecting 'the worried well' from any risks," said UBS analyst Jo Walton. "And if it turns out that re-boosting is not possible, [the decision] keeps the vaccine for use only when a patient is most likely to get a benefit."GSK had also hoped US health authorities would endorse Arexvy for 50-59-year-olds after a recent Food and Drug Administration (FDA) approval for this group. But no such support materialised. According to UBS, this means interested patients would probably have to self-fund their vaccinations at a list price of $300 (£236). Jabs that receive the CDC's seal of approval tend to receive some level of insurance coverage, meaning patients can access them at reduced rates.At present, there isn't enough data on Arexvy's durability for regulators to endorse booster doses and this is crucial for predicting future earnings. Once the results of ongoing trials are published, it's possible that the CDC could expand its recommendations to include vulnerable people in additional age brackets. Brokers are seemingly divided over the longer-term impact of last week's decision, with one Citi analyst stating peak sales of the jab would now "fall materially".Meanwhil |
Posted at 27/6/2024 12:23 by tradermichael GSK pipeline:Phase III: 23 candidates Phase II: 42 candidates Phase I: 22 candidates - across all therapeutic areas According to analysts, GSK price target is 1950.86p with a max estimate of 2580.00p Mean share price target: 2265.43p |
Posted at 03/6/2024 08:21 by waldron GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac CasesJune 03, 2024 at 02:58 am EDT Share (MT Newswires) -- GSK (GSK.L) said Monday it will immediately seek an appeal after a US state court judge agreed that plaintiffs' scientific evidence could be heard in jury trials involving the heartburn drug Zantac and its alleged link to cancer. Judge Vivian Medinilla of the Delaware State Court said "it would be improper to simply dismiss these experts as 'poseurs or witnesses for hire', London's Financial Times reported June 1. The British pharmaceutical company said the recent decision contradicts the federal court's multidistrict litigation ruling in December 2022. It then highlighted the scientific consensus regarding the lack of consistent or reliable evidence that the medication increases the risk of any cancer. GSK noted that the US judge's verdict does not mean the court agrees with the scientific conclusions of the plaintiffs' experts nor does it mean liability. In addition to GSK, pharmaceutical companies that marketed the drug including Sanofi (SAN.PA), Boehringer Ingelheim and Pfizer (PFE.F) are facing similar lawsuits related to Zantac. |
Posted at 24/5/2024 07:07 by panache1 Issued: 23 May 2024, London UK Statement: Zantac (ranitidine) litigation - Valadez and Williams cases · Jury in Valadez case in Illinois state court finds GSK not liable for plaintiff's colorectal cancer· Verdict is consistent with scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer· GSK will continue to vigorously defend itself against all other claims· Next Zantac trial (Williams) due to start in Illinois dismissed GSK plc (LSE/NYSE: GSK) welcomes today's jury verdict in the Valadez case in Illinois state court finding in GSK's favour in the first Zantac case to go to trial. This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims. Prior to this verdict, the court rejected the Plaintiff's ability to request punitive damages. Separately, the company welcomed the recent court ruling dismissing the next Zantac trial (Williams) that was due to start on 23 May 2024. In the Williams case, the Illinois state court dismissed the case before trial on the basis that GSK was not the brand manufacturer of over-the-counter Zantac at the time the Plaintiff allegedly used it and should not be liable for any subsequent over-the-counter Zantac use. ? |
Posted at 02/5/2024 09:24 by geckotheglorious II view”GSK extends share price rally after very healthy results The turnaround at this UK pharmaceutical giant continues following these well-received quarterly results. City writer Graeme Evans explains why investors keep chasing the shares higher. Upgraded guidance and a bigger-than-expected quarterly dividend today moved GSK The drugs giant plans to pay shareholders 15p a share on 11 July, which US bank Jefferies said compared with the City consensus of 14.7p and its own 14.5p estimate. Last year’s quarterly dividend was 14p. The company continues to forecast a full-year payout of 60p a share, which is based on its policy of a 40-60% payout ratio through the investment cycle. Shares rose 40p to 1,713p, taking gains for this year to 16%, after first-quarter revenues of £7.36 billion topped City hopes by 4% and led to a 16% beat on the earnings per share result of 43.1p. The improvement was fuelled by strong sales of shingles vaccine Shingrix, which rose 18% to £945 million on the back of immunisation programmes in Australia and Europe, including the UK. It also benefited from earlier than anticipated supply to GSK’s partner in China. Markets outside the US now represent more than 50% of global Shingrix sales, up from 40% the same quarter a year ago. The vaccine has been launched in 39 countries, the majority of which have average cumulative immunisation rates below 5%. US sales decreased 7% against tougher comparatives, after the country’s immunisation rate at the end of 2023 reached 37% of the more than 120 million US adults currently recommended to receive Shingrix, up seven percentage points since the end of 2022. Arexvy, a respiratory syncytial virus vaccine for older adults, recorded sales of £182 million following its launch in the US in the third quarter of last year. More than seven million of the country’s 83 million adults at risk have so far been protected by Arexvy. In speciality medicines, strong performances in HIV, respiratory and immunology and oncology helped the division’s sales up by 17% to £2.5 billion. Total group sales rose 10% on a constant currency basis, with growth across the first half set to be stronger than the second due to tougher comparisons and the timing of Shingrix sales in China. GSK’s forecasts for 2024 now point to turnover growth towards the upper part of the 5-7% range and core operating profit growth of 9% to 11% compared with 7-10% previously. Core earnings per share growth of 8% to 10% is up from 6-9% given at 2023 results. The drugs pipeline now features 72 vaccines and specialty medicines, with 18 assets in the Phase III later stages of development. Chief executive Emma Walmsley said: “We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data readouts for four phase III medicines.” Taken together with other R&D achievements, she said GSK had strengthened its position in its key therapeutic areas of infectious diseases, HIV, respiratory/immunolo She added: “We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024.”Shares are now within 100p of where they were two years ago prior to the disclosure of US litigation on heartburn drug Zantac. They were just 1,316p in July last year. Jefferies is backing shares to reach 1,950p. It said today: “We are well above consensus 2026 estimates and believe long-acting HIV injectables, vaccines, and new pipeline launches mean profits likely face a blip not cliff on 2028 HIV patent expiries. “We argue given this under-appreciated growth profile, the shares offer attractive risk-reward ahead of potential Zantac class action settlement.” The Zantac issue has overshadowed the company’s attempts to convince the City of its standalone potential since splitting off consumer healthcare operation Haleo It continues to defend itself against the claims but doing so has taken time, with cases scheduled in Illinois, Texas and Nevada between now and March 2025. GSK reached a confidential settlement on a trial due to begin last month in California, a move it said reflected the company’s desire to avoid the distraction related to protracted litigation. It did not admit any liability in the settlement and said it would “continue to vigorously defend itself based on the facts and the science in all other Zantac cases”. |
Posted at 03/4/2024 08:21 by geckotheglorious GSK picking up momentum, says HL’s ClaytonGSK (GSK) is ‘fighting back into contention’ with a bumper crop of new product launches in the pipeline, says Hargreaves Lansdown manager Steve Clayton. Clayton holds the Citywire Elite Companies AAA-rated pharmaceutical giant in his HL Select UK Income Shares fund, where it makes up 3% of the £138m portfolio. The group has been focused on restructuring, with a spin out of its consumer division Haleon (HLN), and developing new medicines such as shingles vaccine Shingrix, which Clayton said is ‘already a multi-billion dollars a year product’. The arrival of US activist investors Elliott Management a few years ago highlighted ‘the weak returns GSK had achieved, despite some real clinical strengths within the business’. ‘The company is now more optimistic about its research pipeline delivering more meaningful new drugs than for many years,’ Clayton said. ‘GSK’s business has more clarity about it these days and its current pipeline of 71 assets is predicted by GSK to contain at least 12 major new products to be launched from 2025 onwards.’ The shares dropped 2.5% to £16.65 on Tuesday, but have added almost 16% over the last 12 months. |
Posted at 11/1/2024 10:11 by anhar MHRANGOON is correct that you have to adjust for the consolidation in order to compare current values with the pre-demerger value. You can't just look at the share prices alone to make a comparison with the pre-demerger value, you need to consider the number of shares involved.The terms were that pre-demerger GSK holders received 1 HLN for every 1 GSK share held. Following that, GSK shares were consolidated at 4 for 5. So assume for example you held 1,000 old GSK, then you would now have 1,000 HLN and 800 current GSK. Using the above figures, the old GSK share price of 1,800p gives a value of £18,000 pre-dem. With new GSK now at 1,570p the holding is worth £12,560 and HLN £3,370, a total of £15,930 which is a loss of £2,070 or 11.5% on the old GSK value. Clearly then, the combined holding would have to rise to £18,000 just to break even, which could be satisfied by GSK or HLN alone or some combination of the two. |
Posted at 10/1/2024 18:17 by laurence llewelyn binliner The pre split share price in summer 2022 was about 1800, and with the share price today at 1570, plus the HLN share price of 337 gives us c1900 total, so we are ahead again at last 18 months later..GSK at 1800 stand alone would be great to see with HLN alongside adding value for those holders who kept them, as soon as they hit their debt to EBITDA ratio the dividend will pick up pace there too.. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
